COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,281 Articles (22,759 medRxiv, 8,522 bioRxiv)

Most recent first Previous |  Page 935: Articles 9341-9350  | Next

Binding Interactions between RBD of Spike-Protein and Human ACE2 in Omicron variant
Jawad, B., Adhikari, P., Podgornik, R., Ching, W.-Y.
10.1101/2022.02.10.480009 — Posted: 2022-02-11
Relation of incident Type 1 diabetes to recent COVID-19 infection: cohort study using e-health record linkage in Scotland
McKeigue, P. M., McGurnaghan, S., Blackbourn, L., Bath, L. E., McAllister, D. A., Caparrotta, T. M., Wild, S. H., Wood, S. N., Stockton, D., Colhoun, H. M.
10.1101/2022.02.11.22270785 — Posted: 2022-02-11
Long term antibody response to SARS-CoV-2 in children
Dunay, G. A., Barroso, M., Woidy, M., Danecka, M. K., Engels, G., Hermann, K., Neumann, F. S., Paul, K., Beime, J., Escherich, G., Fehse, K., Grinstein, L., Haniel, F., Haupt, L. J., Hecher, L., Kehl, T., Kemen, C., Kemper, M. J., Kobbe, R., Kohl, A., Klokow, T., Noerz, D., Olfe, J., Schlenker, F., Schmiesing, J., Schrum, J., Sibbertsen, F., Stock, P., Tiede, S., Vettorazzi, E., Zazara, D. E., Zapf, A., Luetgehetmann, M., Oh, J., Mir, T. S., Muntau, A. C., C19.CHILD Study Group, , Gersting, S. W.
10.1101/2022.02.11.22270611 — Posted: 2022-02-11
SARS-CoV-2 neutralization after mRNA vaccination and variant breakthrough infection
Gaebler, C., DaSilva, J., Bednarski, E., Muecksch, F., Schmidt, F., Weisblum, Y., Millard, K., Turroja, M., Cho, A., Wang, Z., Caskey, M., Nussenzweig, M. C., Bieniasz, P., Hatziioannou, T.
10.1101/2022.02.09.22270692 — Posted: 2022-02-11 Discussion: Onsite
DNA Aptamer Gold Nanoparticle Colorimetric Diagnostic Test Kit of Saliva Samples for SARS-CoV-2 Virus Linked to Mobile Phone Application (AptamexTM).
Chotimah, S. N., Putra, Y. E., Ng, J. H., Tijptaningrum, A., Sahara, N. S., Anti, A., Amaliah, R., Rodriguez, M. O., Llerga, T. M., O Sullivan, C., Goh, S., Tijptaningrum, A.
10.1101/2022.02.09.22269224 — Posted: 2022-02-10
Preclinical establishment of a divalent vaccine against SARS-CoV-2
Wagner, L., Hevesi, Z., Harkany, T., Gerges, D., Schmetterer, K., Pollak, D., Frey, T., Lang, R., Freire, R., Kapps, S., Schmidt, S., Schmidt, A., Winnicki, W.
10.1101/2022.02.10.479919 — Posted: 2022-02-10
Cell delivery peptides for small interfering RNAs targeting SARS-CoV-2 new variants through a bioinformatics and deep learning design
Gonzalez, R. D., Figueiredo, P. R., Carvalho, A. T. P.
10.1101/2022.02.09.479755 — Posted: 2022-02-10
The rise and fall of SARS-CoV-2 variants and the emergence of competing Omicron lineages
Wiegand, T. R., McVey, A., Nemudraia, A., Nemudryi, A., Wiedenheft, B.
10.1101/2022.02.09.479842 — Posted: 2022-02-10
SARS-CoV-2 Nsp1 N-terminal and linker regions as a platform for host translational shutoff
Graziadei, A., Schildhauer, F., Spahn, C., Kraushar, M. L., Rappsilber, J.
10.1101/2022.02.10.479924 — Posted: 2022-02-10
Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variants
Pitts, J., Li, J., Perry, J., Du Pont, V., Riola, N., Rodriguez, L., Lu, X., Kurhade, C., Xie, X., Camus, G., Manhas, S., Martin, R., Shi, P.-Y., Cihlar, T., Porter, D. P., Mo, H., Maiorova, E. S., Bilello, J. P.
10.1101/2022.02.09.479840 — Posted: 2022-02-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).